References
1. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122 (3): 787–95. DOI: https://www.doi.org/10.1172/JCI59643
2. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity. 2010; 32 (5): 593–604. DOI: https://www.doi.org/10.1016/j.immuni.2010.05.007
3. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496 (7446): 445–55. DOI: https://www.doi.org/10.1038/nature12034
4. Zhang L., Zhu H., Lun Y., Yan D., Yu L., Du B., Zhu X. Proteomic analysis of macrophages: a potential way to identify novel proteins associated with activation of macrophages for tumor cell killing. Cell Mol Immunol. 2007; 4 (5): 359–67. PMID: 17976316
5. Pozzi L.-A.M., Maciaszek J.W., Rock K.L. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol. 2005; 175 (4): 2071–81. DOI: https://www.doi.org/10.4049/jimmunol.175.4.2071
6. Wynn T.A., Freund Y.R., Paulnock D.M. TNF-alpha differentially regulates Ia antigen expression and macrophage tumoricidal activity in two murine macrophage cell lines. Cell Immunol. 1992; 140 (1): 184–96. DOI: https://www.doi.org/10.1016/0008-8749(92)90186-s
7. Sun L., Kees T., Almeida A.S., Liu B., He X.Y., Ng D., Han X., Spector D.L., McNeish I.A., Gimotty P., Adams S., Egeblad M. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell. 2021; 39 (10): 1361–74.e9. DOI: https://www.doi.org/10.1016/j.ccell.2021.08.005
8. Singh M., Khong H., Dai Z., Huang X.-F., Wargo J.A., Cooper Z.A., Vasilakos J.P., Hwu P., Overwijk W.W. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014; 193 (9): 4722–31. DOI: https://www.doi.org/10.4049/jimmunol.1401160
9. Hedl M., Yan J., Witt H., Abraham C. IRF5 is required for bacterial clearance in human m1-polarized macrophages, and IRF5 immune-mediated disease risk variants modulate this outcome. J Immunol. 2019; 202 (3): 920–30. DOI: https://www.doi.org/10.4049/jimmunol.1800226
10. Nikonova A.A., Pichugin A.V., Chulkina M.M., Lebedeva E.S., Gaisina A.R., Shilovskiy I.P., Ataullakhanov R.I., Khaitov M.R., Khaitov R.M. The TLR4 agonist immunomax affects the phenotype of mouse lung macrophages during respiratory syncytial virus infection. Acta Naturae. 2018; 10 (4): 95. PMID: 30713767
11. Chi H., Li C., Zhao F.S., Zhang L., Ng T.B., Jin G., Sha O. Anti-tumor activity of toll-Like receptor 7 agonists. Front Pharmacol. 2017. DOI: https://www.doi.org/10.3389/FPHAR.2017.00304
12. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009; 1 (6): 949–64. DOI: https://www.doi.org/10.2217/imt.09.70
13. Ghochikyan A., Pichugin A., Bagaev A., Davtyan A., Hovakimyan A., Tukhvatulin A., Davtyan H., Shcheblyakov D., Logunov D., Chulkina M., Savilova A., Trofimov D., Nelson E.L., Agadjanyan M., Ataullakhanov R.I. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. J Transl Med. 2014. DOI: https://www.doi.org/10.1186/S12967-014-0322-Y
14. Rodell C.B., Arlauckas S.P., Cuccarese M.F., Garris C.S., Li R., Ahmed M.S., Kohler R.H., Pittet M.J., Weissleder R. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018; 2 (8): 578–88. DOI: https://www.doi.org/10.1038/s41551-018-0236-8
15. Ackerman S.E., Pearson C.I., Gregorio J.D., Gonzalez J.C., Kenkel J.A., Hartmann F.J. et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat. Сancer.2021; 2 (1): 18–33. DOI: https://www.doi.org/10.1038/s43018-020-00136-x
16. Zhu P., Hou Y., Tang M., Jin Z., Yu Y., Li D., Yan D., Dong Z. The role of HIF-1α in BCG-stimulated macrophages polarization and their tumoricidal effects in vitro. Med Microbiol Immunol. 2021; 210 (2–3): 149–56. DOI: https://www.doi.org/10.1007/s00430-021-00708-3
17. Kumar P., Tyagi R., Das G., Bhaskar S. Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll-like receptor-dependent manner. Immunology. 2014; 143 (2): 258–68. DOI: https://www.doi.org/10.1111/imm.12306
18. Suarez G., Romero-Gallo J., Piazuelo M.B., Sierra J.C., Delgado A.G., Kay Washington M., Shah S.C., Wilson K.T., Peek Jr R.M. Nod1 imprints inflammatory and carcinogenic responses toward the gastric pathogen Helicobacter pylori. Cancer Res. 2019; 79 (7): 1600–11. DOI: https://www.doi.org/10.1158/0008-5472.CAN-18-2651
19. Punzo F., Bellini G., Tortora C., Di Pinto D., Argenziano M., Pota E., Di Paola A., Di Martino M., Rossi F. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget. 2020; 11 (7): 687–98. DOI: https://www.doi.org/10.18632/oncotarget.27479
20. Ando K., Mori K., Corradini N., Redini F., Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011; 12 (2): 285–92. DOI: https://www.doi.org/10.1517/14656566.2011.543129
21. Budikhina A.S., Murugina N.E., Maximchik P. V., Dagil Y.A., Nikolaeva A.M., Balyasova L.S., Murugin V.V., Selezneva E.M., Pashchenkova Y.G., Chkadua G.Z., Pinegin B.V., Pashenkov M.V. Interplay between NOD1 and TLR4 receptors in macrophages: nonsynergistic activation of signaling pathways results in synergistic induction of proinflammatory gene expression. J Immunol. 2021; 206 (9): 2206–20. DOI: https://www.doi.org/10.4049/jimmunol.2000692
22. Bagaev A.V., Rybinets A.S., Fedorova A.A., Ushakova E.I., Lebedeva E.S., Pichugin A.V., Ataullakhanov R.I. Synergism of TLR3 and TLR4 agonists during reprogramming of macrophages into an antitumor state. Immunologiya. 2021; 42 (6): 615–30. DOI: https://www.doi.org/10.33029/0206-4952-2021-42-6-615-630 (in Russian)
23. Van Heel D.A., Ghosh S., Hunt K.A., Mathew C.G., Forbes A., Jewell D.P., Playford R.J. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn’s disease. Gut. 2005. DOI: https://www.doi.org/10.1136/gut.2005.065888
24. Fritz J.H., Girardin S.E., Fitting C., Werts C., Mengin-Lecreulx D., Caroff M. et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2- activating agonists. Eur J Immunol. 2005; 35 (8): 2459–70. DOI: https://www.doi.org/10.1002/eji.200526286
25. Murad Y.M., Clay T.M., Lyerly H.K., Morse M.A. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther. 2007; 7 (8): 1257–66. DOI: https://www.doi.org/10.1517/14712598.7.8.1257
26. van Heel D.A., Ghosh S., Butler M., Hunt K., Foxwell B.M.J., Mengin-Lecreulx D., Playford R.J. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol. 2005; 35 (8): 2471–6. DOI: https://www.doi.org/10.1002/eji.200526296
27. Girardin S.E., Boneca I.G., Carneiro L.A.M., Antignac A., Jéhanno M., Viala J., Tedin K., Taha M.-K., Labigne A., Zähringer U., Coyle A.J., DiStefano P.S., Bertin J., Sansonetti P.J., Philpott D.J. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science. 2003; 300 (5625): 1584–7. DOI: https://www.doi.org/10.1126/science.1084677
28. Barton G.M., Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol. 2002. DOI: https://www.doi.org/10.1007/978-3-642-59430-4_5